Fused amino pyridine as HSP90 inhibitors

Inventors

Cai, Xiong • Qian, Changgeng • Zhai, Haixiao

Assignees

Curis Inc

Interested in licensing this patent?

MTEC can help explore whether this patent might be available for licensing for your application.

Publication Number

US-10844056-B2

Patent

Publication Date

2020-11-24

Expiration Date


Abstract

The present invention relates to HSP90 inhibitors containing fused amino pyridine core that are useful as inhibitors of HSP90 and their use in the treatment of HSP90 related diseases and disorders such as cancer, an autoimmune disease, or a neurodegenerative disease.

Core Innovation

The invention relates to a compound represented by formula I, or a pharmaceutically acceptable salt, prodrug or solvate thereof, wherein U, W, X, Y, Z, Q, and V are defined by specific structural substituent options. The disclosed chemical space includes thioether-containing heteroaryl scaffolds, including a bicyclic or imidazo[4,5-c]pyridine-type core linked to a substituted aryl portion, with examples showing halogen, methoxy, hydroxy, nitrile, sulfonyl, amino, and cyclic acetal-type substitutions.

The compounds include generalized embodiments described by formulas II-V and representative compounds listed in Table A as example structures. The disclosed forms also include pharmaceutically acceptable salts, prodrugs, solvates, and stereochemical forms such as geometric isomers, enantiomers, diastereomers, and racemates. The examples further vary terminal functionalities, including substituted alkenyl or alkynyl groups and cyano or nitrile-related terminal groups.

The invention describes HSP90 inhibitor compounds defined by formula I and states therapeutic use for HSP90-related diseases, including cancer, autoimmune diseases, and neurodegenerative disorders. The document also references HSP70 co-chaperone context and HSP90 client oncoproteins including EGFR, Raf-1, v-Src, Cdk4, and ErbB-2. The chemistry focuses on specific thioether-containing substitution patterns as reflected in the examples.

Claims Coverage

The claim coverage centers on one independent claim defining a compound by formula I, including pharmaceutically acceptable salt, prodrug or solvate forms, with extensive structural coverage through variable definitions for U, W, X, Y, Z, Q, and V. Dependent claims further cover pharmaceutical compositions and solid dosage forms. In total, the coverage emphasizes the formula I substituent framework and three formulation-related features.

Formula I compound with defined substituent variables

A compound represented by formula I, or a pharmaceutically acceptable salt, prodrug or solvate thereof, wherein U is CH; W is selected from hydrogen, halogen, amino, hydroxy, thiol, alkyl and substituted variants and multiple additional listed substituent categories; X is S; Y is independently selected from hydrogen, halogen, NO2, CN, or lower alkyl; Z is amino or substituted or unsubstituted alkylamino/dialkylamino/alkylcarbonylamino; Q is aryl/substituted aryl/heteroaryl/cycloalkyl/heterocycloalkyl; and V is hydrogen or straight- or branched-substituted or unsubstituted alkyl/alkenyl/alkynyl with one or more methylenes interrupted or terminated by specified heteroatoms or functional groups and by substituted or unsubstituted aryl/heteroaryl/heterocyclic/cycloalkyl.

Pharmaceutical composition including the formula I compound with acceptable carrier or excipient

A pharmaceutical composition that includes the compound represented by formula I together with a pharmaceutically acceptable carrier or excipient.

Solid dosage-form pharmaceutical composition

The pharmaceutical composition is formulated as a tablet, a capsule, a pill, a powder or granules.

Overall, the claim set defines a broad formula I compound class with fixed core choices for U and X and extensive options for W, Y, Z, Q, and V, together with dependent pharmaceutical composition claims and further narrowing to conventional solid dosage forms.

Stated Advantages

Reduces total brain infarct volume in the tMCAO rat model at 4 hours (reported as about 33% reduction).

Favorable PK and brain penetration are stated.

Documented Applications

Hsp90 chaperone refolding inhibition anti-proliferation evaluation using IC50 values in TABLE B.

HSP90 competition binding using fluorescence polarization to obtain binding IC50 values in TABLE B.

In vivo evaluation in a tMCAO rat model with reported reduction of total brain infarct volume after a single iv dose.

Therapeutic use for HSP90-related diseases, including cancer, autoimmune diseases, and neurodegenerative disorders.

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.